Table II. Characteristics of 20 patients found to have “double hit” chronic lymphocytic leukaemia.
Patients with both 17p- and 11q- (“double hit”) were more likely to be males who presented with more advanced stage disease, unmutated IGHV, and to be previously treated at the time of the sentinel FISH event. Overall, 4/20 patients (20%) had at least one clonal evolution event prior to acquisition of the double hit.
| Patient demographics | FISH Testing (%) | Laboratory Results | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Sex | Age at Diagnosis (years) |
Survival Status |
OS | Tx Status |
TTT | Rai stage |
11q- (ATM) |
17p- (TP53) |
17p- & 11q- |
Clonality | CD38 | ZAP70 |
IGHV Mut |
TP53 Mut |
| 1 | F | 76 | Dead | 3.57 | − | 0.04 | na | 10 | 11 | 58 | “Double Hit” | + | na | na | na |
| 2 | M | 42 | Dead | 0.86 | + | 0.05 | IV | − | − | 94 | “Double Hit” | + | + | − | + |
| 3 | M | 65 | Dead | 0.28 | + | 0.02 | I | − | − | 37 | “Double Hit” | na | na | na | na |
| 4 | F | 49 | Dead | 2.98 | + | 1.28 | I | − | 15 | 35 | “Double Hit”* | − | − | + | + |
| 5 | M | 59 | Dead | 2.14 | + | 0.10 | I | − | 55 | 8 | “Double Hit”* | − | − | + | + |
| 6 | M | 75 | Dead | 2.45 | + | 0.05 | 0 | − | 62 | 30 | “Double Hit”* | + | − | − | + |
| 7 | M | 64 | Dead | 1.41 | + | 0.04 | 0 | − | − | 86 | “Double Hit” | − | na | − | + |
| 8 | F | 70 | Dead | 2.55 | + | 0.01 | III | − | − | 88 | “Double Hit” | + | + | − | + |
| 9 | M | 63 | Dead | 0.06 | + | 0.01 | III | − | 65 | 32 | “Double Hit”* | + | − | − | − |
| 10 | F | 63 | Dead | 1.62 | + | 0.05 | 0 | − | − | 92 | “Double Hit” | − | + | − | + |
| 11 | M | 42 | Dead | 1.85 | + | 0.25 | I | 20 | − | 64 | “Double Hit”^ | + | − | − | +# |
| 12 | M | 67 | Dead | 1.45 | + | 0.04 | IV | 8 | − | 59 | “Double Hit ^ | + | na | na | na |
| 13 | M | 62 | Alive | 2.69 | + | 0.07 | I | − | − | 67 | “Double Hit” | + | − | na | na |
| 14 | M | 35 | Alive | 1.60 | + | 1.57 | I | − | 52 | 47 | “Double Hit”* | + | − | + | + |
| 15 | M | 76 | Dead | 1.03 | + | 0.12 | I | 14 | − | 77 | “Double Hit”^ | − | + | − | + |
| 16 | M | 60 | Alive | 1.97 | + | 1.50 | I | − | − | 71 | “Double Hit” | − | + | − | + |
| 17 | M | 56 | Alive | 1.21 | + | 0.07 | IV | − | − | 46 | “Double Hit” | − | + | − | − |
| 18 | M | 52 | Dead | 0.88 | + | 0.06 | I | − | 22 | 17 | “Double Hit”* | − | + | − | − |
| 19 | F | 78 | Alive | 0.43 | − | 0.43 | 0 | − | − | 84 | “Double Hit” | − | − | + | na |
| 20 | M | 64 | Alive | 0.00 | + | 0.00 | 0 | − | 52 | 42 | “Double Hit”* | + | + | − | − |
OS, overall survival; Tx, treatment; TTT, time to treatment from sentinel fluorescence in situ hybridization (FISH); Normal cutoffs for FISH testing: 11q- (6.0%), 17p- (7.0%), 17p- and 11q- (2.5%); IGHV Mut, results for IGHV somatic hypermutation testing; TP53 Mut, results for TP53 mutation testing;
double hit with separate 17p- clone;
double hit with separate 11q- clone;
2 different TP53 mutations seen in this patient;
na, not available.